Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I, Novello S, Gubens MA, Boyer M, Su WC, Samkari A, Jensen EH, Kobie J, Piperdi B, Baas P.
Herbst RS, et al. Among authors: gervais r.
J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
J Thorac Oncol. 2021.
PMID: 34048946
Free article.
Clinical Trial.
Exploratory biomarker analysis revealed that higher tissue tumor mutational burden (175 mutations per exome) was associated with improved outcomes with pembrolizumab. CONCLUSIONS: Pembrolizumab continued to provide long-term benefit than docetaxel in patients with previous …
Exploratory biomarker analysis revealed that higher tissue tumor mutational burden (175 mutations per exome) was associated with improved ou …